Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 3-hydroxy-4-methoxy-alpha-(3,4,5-trimethoxyphenyl)benzeneethanol
2. Nsc 348103
3. Nsc-348103
1. (-)-combretastatin
2. (r)-(-)-combretastatin
3. 82855-09-2
4. Combretastatin, (-)-
5. 7o62j06f18
6. Nsc-348103
7. 3-hydroxy-4-methoxy-alpha-(3,4,5-trimethoxyphenyl)benzeneethanol
8. Unii-7o62j06f18
9. Nsc 348103
10. Combretastatin [mi]
11. Schembl19955
12. Chembl246600
13. Dtxsid80897571
14. Zinc1607492
15. Db12596
16. Q5150954
17. 5-[(2r)-2-hydroxy-2-(3,4,5-trimethoxyphenyl)ethyl]-2-methoxyphenol
18. Benzeneethanol, 3-hydroxy-4-methoxy-alpha-(3,4,5-trimethoxyphenyl)-, (r)-
19. Benzeneethanol, 3-hydroxy-4-methoxy-.alpha.-(3,4,5-trimethoxyphenyl)-, (r)-
20. Benzeneethanol, 3-hydroxy-4-methoxy-alpha-(3,4,5-trimethoxyphenyl)-, (alphar)-
| Molecular Weight | 334.4 g/mol |
|---|---|
| Molecular Formula | C18H22O6 |
| XLogP3 | 2.6 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 7 |
| Exact Mass | 334.14163842 g/mol |
| Monoisotopic Mass | 334.14163842 g/mol |
| Topological Polar Surface Area | 77.4 Ų |
| Heavy Atom Count | 24 |
| Formal Charge | 0 |
| Complexity | 351 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Antineoplastic Agents, Phytogenic
Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. (See all compounds classified as Antineoplastic Agents, Phytogenic.)
Tubulin Modulators
Agents that interact with TUBULIN to inhibit or promote polymerization of MICROTUBULES. (See all compounds classified as Tubulin Modulators.)
ABOUT THIS PAGE
A Combretastatin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Combretastatin, including repackagers and relabelers. The FDA regulates Combretastatin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Combretastatin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Combretastatin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Combretastatin supplier is an individual or a company that provides Combretastatin active pharmaceutical ingredient (API) or Combretastatin finished formulations upon request. The Combretastatin suppliers may include Combretastatin API manufacturers, exporters, distributors and traders.
click here to find a list of Combretastatin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
Combretastatin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Combretastatin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Combretastatin GMP manufacturer or Combretastatin GMP API supplier for your needs.
A Combretastatin CoA (Certificate of Analysis) is a formal document that attests to Combretastatin's compliance with Combretastatin specifications and serves as a tool for batch-level quality control.
Combretastatin CoA mostly includes findings from lab analyses of a specific batch. For each Combretastatin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Combretastatin may be tested according to a variety of international standards, such as European Pharmacopoeia (Combretastatin EP), Combretastatin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Combretastatin USP).
LOOKING FOR A SUPPLIER?
